Research programme: aptamer-based therapeutics - Archemix/GlaxoSmithKline

Drug Profile

Research programme: aptamer-based therapeutics - Archemix/GlaxoSmithKline

Latest Information Update: 19 Apr 2011

Price : $50

At a glance

  • Originator Archemix Corporation; GlaxoSmithKline
  • Developer Archemix Corporation
  • Class Oligonucleotides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 23 Dec 2008 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top